JPH02311414A - Skin drug for external use - Google Patents
Skin drug for external useInfo
- Publication number
- JPH02311414A JPH02311414A JP13538089A JP13538089A JPH02311414A JP H02311414 A JPH02311414 A JP H02311414A JP 13538089 A JP13538089 A JP 13538089A JP 13538089 A JP13538089 A JP 13538089A JP H02311414 A JPH02311414 A JP H02311414A
- Authority
- JP
- Japan
- Prior art keywords
- water
- skin
- nitrocellulose
- agent
- soluble polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title abstract description 5
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 17
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 17
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract description 24
- 239000000126 substance Substances 0.000 abstract description 7
- 239000000839 emulsion Substances 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000000739 antihistaminic agent Substances 0.000 abstract description 3
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 229940125715 antihistaminic agent Drugs 0.000 abstract description 2
- 239000000645 desinfectant Substances 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract description 2
- -1 germicide Substances 0.000 abstract description 2
- 239000003906 humectant Substances 0.000 abstract description 2
- 239000004014 plasticizer Substances 0.000 abstract description 2
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 230000002070 germicidal effect Effects 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- 239000000203 mixture Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010020649 Hyperkeratosis Diseases 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000003643 Callosities Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940024473 salicylic acid emollient and protective preparations Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、皮膚に対する軟化作用を改良した皮膚外用剤
に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a skin preparation for external use that has an improved softening effect on the skin.
[従来の技術およびその課題]
従来より、皮膚を薬品や他の刺激性物質などから守るた
めの皮膚保護剤が一般に知られている。[Prior Art and its Problems] Skin protective agents for protecting the skin from drugs and other irritating substances have been generally known.
この皮膚保護剤は、皮膚に親和性のある膜形成剤を含む
溶液を皮膚に塗布して保護膜を形成させることにより皮
膚の保護を図るもので、たとえば、炊事、洗濯、水仕事
などによって引き起こされる手指の皮膚炎、ざざくれ、
爪われ、あるいは切傷、すり傷、あかぎれ、ひびなどの
治療に、患部の被覆、保護を目的とした外用剤が広く利
用されている。This skin protectant protects the skin by applying a solution containing a film-forming agent that is compatible with the skin to the skin to form a protective film. dermatitis on the fingers, prickles,
BACKGROUND OF THE INVENTION External preparations for covering and protecting the affected area are widely used to treat nail wounds, cuts, abrasions, chaps, cracks, and the like.
このような外用剤としては、たとえばコロジオンと呼ば
れるニトロセルロースをエーテルとエタノールの混液に
溶解した溶液が古くから知られている。As such external preparations, for example, a solution of nitrocellulose called collodion dissolved in a mixture of ether and ethanol has been known for a long time.
しかし、コロジオン膜の皮膚に対する付着性は不十分で
あり、使用時の屈曲、水濡れなどにより剥離を生じ易い
という欠点がある。この改良品として、コロジオンにと
マシ油を添加した弾性コロジオンが開発されているが、
ヒマシ油の添加により組成物の疎水性が強くなり、皮膚
面に僅かの水分があっても剥がれ易くなってしまう。ま
た、ニトロセルロースは、水や油に不溶性であるため、
一度皮膚に対して強く付着してしまうと、ラッカーシン
ナーまたはエナメルリムーバーのような特別な除去液を
使用しないと除去することができない、などの問題があ
った。However, the adhesion of the collodion film to the skin is insufficient, and there is a drawback that it is easily peeled off due to bending during use, wetting with water, etc. As an improved product, elastic collodion has been developed by adding mustard oil to collodion.
The addition of castor oil increases the hydrophobicity of the composition, making it easy to peel off even if there is a small amount of moisture on the skin surface. In addition, nitrocellulose is insoluble in water and oil, so
Once adhered strongly to the skin, there are problems such as that it cannot be removed without using a special removal solution such as lacquer thinner or enamel remover.
一方、皮膚角質改善を目的として、荒れた踵、魚の目、
タコなどを溶解・除去するための薬剤としてサリチル酸
軟膏が古くから知られているが、速乾性に欠け、使用性
の面でも「べたつく」などの問題があった。また、溶剤
系のサリチル酸製剤においては、患部への水分補給に欠
け、「ひりつり」「シみる」などの刺激感が問題とされ
ている。On the other hand, for the purpose of improving skin keratin, it is used to treat rough heels, corns, and corns.
Salicylic acid ointment has been known for a long time as a drug for dissolving and removing calluses, etc., but it lacks quick drying properties and has problems in terms of usability, such as being sticky. In addition, solvent-based salicylic acid preparations lack hydration to the affected area and cause irritation such as ``tingling'' and ``stinging''.
[課題を解決するための手段]
本発明者らは、以上述べたような従来の課題を解決すべ
く鋭意研究を重ねた結果、ニトロセルロース、溶剤を含
有する油性剤に水溶性高分子水溶液をW10乳化型の形
態で特定量配合したならば、皮膚に対する軟化作用に優
れ、しかも皮膚への付着性に優れながらも、洗浄・除去
が容易な皮膚外用剤が得られるということを見い出し、
この知見に基づいて本発明を完成するに至った。[Means for Solving the Problems] As a result of intensive research in order to solve the conventional problems as described above, the present inventors have developed an aqueous solution of a water-soluble polymer in an oil-based agent containing nitrocellulose and a solvent. We have discovered that if a specific amount of W10 is blended in the form of an emulsion, a skin preparation for external use can be obtained that has excellent softening effects on the skin, has excellent adhesion to the skin, and is easy to clean and remove.
Based on this knowledge, we have completed the present invention.
すなわち、本発明はニトロセルロースおよび溶剤を含む
油性剤と、水溶性高分子を含む水溶液とか油中水型(W
/O型)に乳化されてなることを特徴とする皮膚外用剤
である。That is, the present invention uses an oil-based agent containing nitrocellulose and a solvent, and an aqueous solution or water-in-oil (W) containing a water-soluble polymer.
/O type) is an emulsified product for external use on the skin.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
水溶性高分子としては、セルロース系、アクリル系、ビ
ニル系、ポリアミド系、タンパク系等を使用することが
できる。たとえば、ヒドロキシエチルセルロース(ナト
ロゾール0250LR1米国バーキュレス等)、ヒドロ
キシプロピルメチルセルロース(メトローズ”TC−5
、信越化学等)、メタクリル酸エステル両性重合体(ユ
カフォーマー〇AM−75W、WH1三菱油化等)、ポ
リアクリル酸Na(アロン”A−20p、東亜合成化学
等)、ポリビニルアルコール
本合成化学工業等)、メチルビニルエーテル・無水マレ
イン酸コポリマー(ガントレッツ■AN−119、ゼネ
ラルアニリン等)、ポリエチレンオキサイド(PEO
−1、製鉄化学工業等)、α−(N−ジメチルアミノ
)−εー力プロラクタムーεーカプロラクタム共重合変
性ナイロン(AQ−ナイロン0、東し等)、カゼインN
a、ゼラチン、ヒアルロン酸またはその塩類(分子量1
万〜220万)等を挙げることができる。As the water-soluble polymer, cellulose-based, acrylic-based, vinyl-based, polyamide-based, protein-based, etc. can be used. For example, hydroxyethylcellulose (Natrozol 0250LR1 American Vercules, etc.), hydroxypropyl methylcellulose (Metrose" TC-5
, Shin-Etsu Chemical, etc.), methacrylic acid ester amphoteric polymers (Yukaformer AM-75W, WH1 Mitsubishi Yuka, etc.), polyacrylic acid Na (Aron" A-20p, Toagosei Chemical, etc.), polyvinyl alcohol Honsei Kagaku Kogyo, etc. ), methyl vinyl ether/maleic anhydride copolymer (Gantrez AN-119, General Aniline, etc.), polyethylene oxide (PEO
-1, Steel Chemical Industry, etc.), α-(N-dimethylamino)-ε-prolactam ε-caprolactam copolymerized modified nylon (AQ-nylon 0, Toshi, etc.), casein N
a, gelatin, hyaluronic acid or its salts (molecular weight 1
10,000 to 2,200,000).
水溶性高分子の配合量は、水溶性高分子水溶液の形でW
/O型に乳化された皮膚外用剤の内相を形成していれば
よく、特に限定されないが、好ましくは水溶性高分子水
溶液として、製剤全量中0、5〜30重量%(以下、単
に%と称す)、特に好ましくは1〜25%である。水溶
性高分子水溶液の配合量が少なすぎると皮膚に対する軟
化作用が充分期待できず、一方、多すぎると皮膚への付
着性が低下して、「たれおち」が認められてくるので好
ましくない。ざらに、水溶性高分子は、水に対して0.
3〜20%の範囲で選択されるのがよく、より好ましく
は0.5〜15%である。水溶性高分子の配合量が少な
すぎるとW10乳化系の分離安定性が悪くなりやすく、
一方、多すぎると「べたつき」等の使用性が不良となり
やすい。The amount of water-soluble polymer blended is W in the form of a water-soluble polymer aqueous solution.
It is sufficient that the internal phase of the skin external preparation is emulsified in /O type, and is preferably 0.5 to 30% by weight (hereinafter simply %) in the form of a water-soluble polymer aqueous solution, although it is not particularly limited. ), particularly preferably from 1 to 25%. If the amount of the water-soluble polymer aqueous solution blended is too small, a sufficient softening effect on the skin cannot be expected, while if it is too large, the adhesion to the skin will decrease and "sagging" will be observed, which is not preferable. Roughly speaking, water-soluble polymers are 0.0% relative to water.
It is preferably selected in the range of 3 to 20%, more preferably 0.5 to 15%. If the amount of water-soluble polymer blended is too small, the separation stability of the W10 emulsion system tends to deteriorate.
On the other hand, if the amount is too high, usability such as "stickiness" tends to be poor.
本発明で用いられるニトロセルロースは、従来用いられ
てきた周知のものを使用することができる。たとえば、
ニトロセルロース1/4秒、ニトロセルロース1/2秒
、ニトロセルロース2秒、ニトロセルロース7秒、ニト
ロセルロース20秒などが挙げられる。これらの中から
1種または2種以上が任意に選択される。As the nitrocellulose used in the present invention, any conventionally known nitrocellulose can be used. for example,
Examples include nitrocellulose 1/4 second, nitrocellulose 1/2 second, nitrocellulose 2 seconds, nitrocellulose 7 seconds, and nitrocellulose 20 seconds. One or more types are arbitrarily selected from these.
配合量は、一般的には30%のIPA(イソプロピルア
ルコール)湿潤度で5〜25%でおる。The blending amount is generally 5 to 25% with an IPA (isopropyl alcohol) wetness of 30%.
本発明で用いられる溶剤は、従来用いられてきたエステ
ル系、アルコール系、炭化水素系の周知のものを使用す
ることができる。たとえば、酢酸エチル、酢酸ブチル、
酢酸アミル、エチルアルコール、イソプロピルアルコー
ル、ブチルアルコール、トルエンなどが挙げられる。こ
れらの中から1種または2種以上が任意に選択される。As the solvent used in the present invention, conventionally known ester-based, alcohol-based, and hydrocarbon-based solvents can be used. For example, ethyl acetate, butyl acetate,
Examples include amyl acetate, ethyl alcohol, isopropyl alcohol, butyl alcohol, and toluene. One or more types are arbitrarily selected from these.
配合量は、一般的には30〜85%である。The blending amount is generally 30 to 85%.
本発明の皮膚外用剤は、上記の必須成分に加えて、必要
に応じて、樹脂、可塑剤、保湿剤等が配合される。In addition to the above-mentioned essential ingredients, the skin external preparation of the present invention may contain resins, plasticizers, humectants, etc., as necessary.
また、所望により、消毒剤、殺菌剤、鎮痛剤、消炎剤、
抗ヒスタミン剤、ビタミン剤その伯の添加物を含んでも
よい。たとえば、イソプロピルメチルフェノールのよう
な殺菌剤は、本外用剤を創傷に適用したとき殺菌汚染を
防止し、または、汚染による炎症を消炎するのに有効で
ある。また水仕事などにより引き起こされる手のひび、
あかぎれなどに対して、殺菌剤入りの本発明の外用剤を
塗布しておけば、悪化を防ぐと同時に創面の癒着を促進
する。なお、この際、本外用剤中に酢酸トコフェロール
、アスコルビン酸等の末梢血管拡張作用、抗ヒスタミン
作用を有する薬物を添加しておけば、凍傷の予防や治療
にも効果を期待しうる。In addition, disinfectants, bactericidal agents, analgesics, anti-inflammatory agents,
Antihistamines, vitamins, and other additives may also be included. For example, a bactericidal agent such as isopropylmethylphenol is effective in preventing bactericidal contamination or extinguishing inflammation caused by contamination when the topical preparation is applied to a wound. Cracks in hands caused by water work, etc.
Applying the external preparation of the present invention containing a bactericide to chapped wounds will prevent deterioration and at the same time promote healing of the wound surface. At this time, if a drug having peripheral vasodilatory action and antihistamine action, such as tocopherol acetate or ascorbic acid, is added to this external preparation, it can be expected to be effective in preventing and treating frostbite.
同様に、本外用剤中に角質溶解作用を有する物質、たと
えばサリチル酸、尿素、乳酸、アミノ酸類、ピロリドン
カルボン酸、1種または2種以上の界面活性剤の単独あ
るいは組み合わせなどを含有させたものは、皮膜中に配
合された該物質が角化した皮膚に対し、長時間にわたり
持続的に作用するので、タコや魚の目の治療に顕著な効
果がある。Similarly, this topical preparation contains substances with keratolytic action, such as salicylic acid, urea, lactic acid, amino acids, pyrrolidone carboxylic acid, and one or more surfactants alone or in combination. Since the substance contained in the film acts continuously on keratinized skin over a long period of time, it has a remarkable effect on the treatment of calluses and corns.
(以下余白)
[実施例]
次に、実施例および比較例によって、本発明を更に詳細
に説明する。なお、本発明はこれにより限定されるもの
ではない。配合量は重量%である。(The following is a blank space) [Example] Next, the present invention will be described in more detail with reference to Examples and Comparative Examples. Note that the present invention is not limited to this. The blending amount is in weight%.
実施例1,2、比較例1.2
第1表に記載した成分および配合量を用いて皮膚外用剤
を製造した。各製法は次の通りである。Examples 1 and 2, Comparative Example 1.2 External skin preparations were manufactured using the ingredients and amounts listed in Table 1. Each manufacturing method is as follows.
(実施例1,2の製法)
■、■、■を混合したものに、■、■、■を添加し、攪
拌溶解する。次いで、■、■を添加し、均一に攪拌(乳
化)して目的の製剤を得た。(Production method of Examples 1 and 2) To a mixture of (1), (2), and (2), (1), (2), and (2) are added and dissolved with stirring. Next, (1) and (2) were added and uniformly stirred (emulsified) to obtain the desired formulation.
(比較例1の製法)
■、■、■を混合したものに、■、■を添加し、攪拌溶
解して目的の製剤を得た。(Production method of Comparative Example 1) ■ and ■ were added to a mixture of ■, ■, and ■, and the mixture was stirred and dissolved to obtain the desired formulation.
(比較例2の製法) ■に■を添加し、攪拌溶解して目的の製剤を得た。(Production method of Comparative Example 2) (2) was added to (2), and the mixture was stirred and dissolved to obtain the desired formulation.
第 1 表
”)HPMC:ヒドロキシプロピルメチルセルロース
”)IPA湿潤度30%
皮膚軟化作用の評価
皮膚軟化作用を評価するためにモルモットから角質層を
採取した。すなわち、モルモットをバリカン・脱毛剤等
により脱毛し、紅斑等がおさまってから皮膚仝層をハサ
ミにて剥離する。剥離後、皮下脂肪をハサミで切除した
のち、60℃の温水中で1分間浸漬し、水冷し、表皮を
ピンセットできれいに剥離する。その表皮を0.1%ト
リプシン溶液(buffer pH7,8> テ37°
C−30分間処理し、生細胞を消化し、角質層を得る。Table 1 "HPMC: Hydroxypropyl Methyl Cellulose") IPA wettability 30% Evaluation of emollient effect In order to evaluate the emollient effect, the stratum corneum was collected from guinea pigs. That is, the hair of the guinea pig is removed using clippers, a depilatory agent, etc., and after the erythema has subsided, the skin layer is peeled off using scissors. After peeling, the subcutaneous fat is excised with scissors, then immersed in warm water at 60°C for 1 minute, cooled in water, and the epidermis is peeled cleanly with tweezers. The epidermis was soaked in a 0.1% trypsin solution (buffer pH 7,8 > 37°
C- Treat for 30 minutes to digest living cells and obtain stratum corneum.
その角質層を、水洗・乾燥して試験に供した。角質層は
2゜X3mmの切片とし、これに実施例1.2および比
較例1,2の各試料を塗布し、連続動的粘弾性測定器に
より、25℃、50%RH条件で、角質層の柔軟性を測
定した。The stratum corneum was washed with water, dried, and used for testing. The stratum corneum was cut into a 2° x 3 mm section, each sample of Example 1.2 and Comparative Examples 1 and 2 was coated on it, and the stratum corneum was measured using a continuous dynamic viscoelasticity meter at 25°C and 50% RH. The flexibility of the material was measured.
第1図は角質層の軟化効果を、処理前の動的粘弾性率(
E−)と処理後の経時動的粘弾性率1=0
(E−一の比で表したものである。動的粘弾性率は、角
質層を採取し、それを引き伸ばすのに要する力を示すも
ので、角質層が軟化するほど動的粘弾性率は低くなる。Figure 1 shows the softening effect of the stratum corneum, the dynamic viscoelastic modulus (
E-) and the time-dependent dynamic viscoelastic modulus after treatment 1 = 0 (E-1).The dynamic viscoelastic modulus is the ratio of the force required to collect and stretch the stratum corneum. The softer the stratum corneum, the lower the dynamic viscoelastic modulus.
同図からも明らかなように、水を配合した実施例の製剤
は、比較例に対して有為に軟化効果に優れていた。As is clear from the figure, the formulations of Examples containing water had significantly better softening effects than Comparative Examples.
実施例3〜8、比較例3
第2表に記載した成分および配合量を用いて皮膚外用剤
を製造した。各製法は次の通りである。Examples 3 to 8, Comparative Example 3 External skin preparations were manufactured using the ingredients and amounts listed in Table 2. Each manufacturing method is as follows.
(比較例3の製法)
■、◎を混合したものに、■、■を添加し、攪拌溶解す
る。次いで■、■を添加し、均一に攪拌(乳化)し、目
的の製剤を得た。(Manufacturing method of Comparative Example 3) ■ and ■ were added to the mixture of ■ and ◎, and the mixture was stirred and dissolved. Next, (1) and (2) were added and uniformly stirred (emulsified) to obtain the desired formulation.
(実施例3〜8の製法)
■、0を混合したものに、■、■を添加し、攪拌溶解す
る。次いで、■〜■のいずれかと■を添加し、均一に攪
拌(乳化)し、目的の製剤を得た。(Production method of Examples 3 to 8) To a mixture of (1) and (0), (1) and (2) were added and dissolved with stirring. Next, any one of ■ to ■ and ■ were added and uniformly stirred (emulsified) to obtain the desired formulation.
(以下余白)
前記の各組成物について、分離(乳化)安定性、塗り易
さくたれおち)、塗布時の刺激について試験をした。試
験および評価は以下の通りに実施した。(Hereinafter, blank space) Each of the above compositions was tested for separation (emulsification) stability, ease of application (relaxation), and irritation during application. Tests and evaluations were conducted as follows.
分離(乳化)安定性
各試料を50 dのがラスピン2本にそれぞれ充填し、
これらを室温および50℃で1週間放置し、それぞれの
分離の状態を評価した。評価は以下の通りである。Separation (emulsification) stability Each sample was packed into two 50 d Laspin tubes,
These were left at room temperature and 50° C. for one week, and the state of each separation was evaluated. The evaluation is as follows.
◎ (良好)・・・両方とも全く分離しなかった○(や
や良好)・・・いずれか一方または両方がわずかに分離
した
△(やや不良)・・・いずれか一方または両方が分離し
た
× (不良)・・・いずれか一方または両方が非常に分
離した
塗り さくたれおち)
各試料2mlをスライドグラスの中央に滴下し、1分後
にスライドグラスを45°に傾けて、それぞれのたれお
ちの程度を評価した。◎ (Good)...Both were not separated at all ○(Slightly good)...One or both were slightly separated △(Slightly poor)...One or both were separated × ( Poor)...either one or both of the coatings are very separated. Drop 2 ml of each sample onto the center of the slide glass, and after 1 minute, tilt the slide glass at 45° to check the extent of each drip. was evaluated.
◎ (良好)・・・全くたれおちが認められなかった
○(ヤヤ良好)・・・たれおちは認められたが、スライ
ドグラス上にとどまった
Δ(やや不良)・・・ゆっくりと流れ落ちたX (不良
)・・・すばやく流れ落ちてしまった塗布時の刺激(ひ
りつき感)
試料を107の筆つきガラスビンに充填し、20名のパ
ネルを用い、手の甲に適量を塗布し、ひりつき感を評価
した。評価は、刺激を感じたパネル数に従って以下の通
りに行った。◎ (Good)... No dripping was observed at all ○ (Good)... Dragging was observed, but it remained on the slide glass ∆ (Slightly poor)... It slowly ran down (Poor)...Irritation when applied (stinging sensation) as it quickly ran down. Fill a glass bottle with a 107 brush with the sample, apply an appropriate amount to the back of the hand using a panel of 20 people, and evaluate the stinging sensation. did. Evaluation was performed as follows according to the number of panels that felt stimulation.
圧−一−−−廼 刺激を感じたパネル数◎(良好
) 0〜5名
O(やや良好) 6〜10名△(やや不良
)11〜15名
X(不良)16〜20名
結果を第3表に示した。Number of panels that felt irritation ◎ (good) 0 to 5 people O (slightly good) 6 to 10 people △ (slightly bad) 11 to 15 people X (poor) 16 to 20 people It is shown in Table 3.
第 3 表
実施例9
■精 製 水 15.O
■濃グリセリン 3.0
■尿 素 2.
0■ポリビニルアルコール 2.0■ニトロ
セルロースHIG−20s、。Table 3 Example 9 ■Purified water 15. O
■Concentrated glycerin 3.0 ■Urea 2.
0 ■ Polyvinyl alcohol 2.0 ■ Nitrocellulose HIG-20s.
(、IPA湿潤度30%)
■イソプロピルアルコール 3.0■酢酸ト
コフエロール 1,0■イソプロピルメ
チルフエノール 0.1■クエン酸トリエチル
2.0[株]酢 酸 エ チ ル
残部■、■、■、[株]を攪拌混合し、これに■
、■を添加し、攪拌溶解する。次いで、このものに、■
を■に溶解したものに■、■を添加したものを添加し、
均一に攪拌(乳化)して目的の製剤を得た。得られた製
剤は、分離安定性、塗り易さ、塗布時の刺激が共に良好
なものであった。(, IPA wetness 30%) ■ Isopropyl alcohol 3.0 ■ Tocopherol acetate 1.0 ■ Isopropyl methylphenol 0.1 ■ Triethyl citrate
2.0 [stock] ethyl acetate
Stir and mix the remaining ■, ■, ■, [stock], and add ■ to this.
, ■ and stir to dissolve. Next, to this one, ■
Add ■ and ■ to the solution of ■,
The desired formulation was obtained by uniformly stirring (emulsifying). The obtained formulation had good separation stability, ease of application, and irritation during application.
実施例10
■精 製 水 20.O
■1,3−ブチレングリコール 4.0■ドデシル
ジメチルアミンオキシド 0.2■ドデシル硫酸ナトリ
ウム 0.06■ヒドロキシエチルセルロース
2.0■n−ブチルアルコール 3゜
40■ニトロセルロースRIG−71o、 。Example 10 ■ Purified water 20. O
■1,3-butylene glycol 4.0■Dodecyldimethylamine oxide 0.2■Sodium dodecyl sulfate 0.06■Hydroxyethylcellulose 2.0■n-butyl alcohol 3°40■Nitrocellulose RIG-71o.
(IPA湿潤度30%)
■ヒ マ シ 油 3
.0■酢 酸 ブ チ ル 残部■、■
、■を攪拌混合し、これに■を添加し、攪拌溶解する。(IPA humidity 30%) ■Castor oil 3
.. 0 ■Butyl acetic acid Remainder■,■
, ■ are stirred and mixed, and ■ is added thereto, and stirred and dissolved.
次いで、このものに、■に■、■。Then, to this one, ■ to ■, ■.
■、■を攪拌溶解したものを添加し、均一に攪拌(乳化
)して目的の製剤を得た。得られた製剤は。A stirred and dissolved solution of (1) and (2) was added and uniformly stirred (emulsified) to obtain the desired formulation. The obtained formulation is.
分離安定性、塗り易さ、塗布時の刺激が共に良好なもの
であった。Separation stability, ease of application, and irritation during application were all good.
[発明の効果]
以上説明したように、本発明の皮膚外用剤は、水を配合
することにより皮膚に対する軟化作用に優れ、しかも皮
膚への付着性、使用後の除去しヤすざなとも極めて良好
なものである。このため、各種の皮膚保護剤や角質除去
剤として巾広い利用が可能である。[Effects of the Invention] As explained above, the skin external preparation of the present invention has an excellent softening effect on the skin by incorporating water, and also has excellent adhesion to the skin and ease of removal after use. It is something. Therefore, it can be widely used as a variety of skin protectants and exfoliants.
第1図は、本発明の実施例を用いた角質層の動的粘弾性
重比の時間変化を比較例を用いた場合と併せて示した特
性図である。
出 願 人 株式会社 資 生 堂E’t /
E”t= 。
団 −1%CI−1FIG. 1 is a characteristic diagram showing temporal changes in the dynamic viscoelastic gravity ratio of the stratum corneum using an example of the present invention, together with a comparative example. Applicant: Shiseido E't Co., Ltd.
E"t= . group -1%CI-1
Claims (1)
溶性高分子を含む水溶液とが油中水型(W/O型)に乳
化されてなることを特徴とする皮膚外用剤。(1) An external preparation for skin, characterized in that an oil-based agent containing nitrocellulose and a solvent and an aqueous solution containing a water-soluble polymer are emulsified into a water-in-oil type (W/O type).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13538089A JPH02311414A (en) | 1989-05-29 | 1989-05-29 | Skin drug for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13538089A JPH02311414A (en) | 1989-05-29 | 1989-05-29 | Skin drug for external use |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02311414A true JPH02311414A (en) | 1990-12-27 |
Family
ID=15150357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13538089A Pending JPH02311414A (en) | 1989-05-29 | 1989-05-29 | Skin drug for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH02311414A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007015973A (en) * | 2005-07-07 | 2007-01-25 | Nippon Kenko Kagaku Kenkyu Center:Kk | Film preparation for bathing |
JP2008105979A (en) * | 2006-10-24 | 2008-05-08 | Nippon Kenko Kagaku Kenkyu Center:Kk | Film guard preparation |
JP2013507367A (en) * | 2009-10-08 | 2013-03-04 | エムエスデー・コンシユーマー・ケア・インコーポレイテツド | Low ether composition and delivery device |
KR20140007923A (en) * | 2011-03-25 | 2014-01-20 | 라보라뚜와르 어르고 | Composition containing a cellulose, a vegetable oil and a volatile solvent, and use thereof as a dressing |
WO2014104149A1 (en) * | 2012-12-28 | 2014-07-03 | 大正製薬株式会社 | Preparation for application to skin |
-
1989
- 1989-05-29 JP JP13538089A patent/JPH02311414A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007015973A (en) * | 2005-07-07 | 2007-01-25 | Nippon Kenko Kagaku Kenkyu Center:Kk | Film preparation for bathing |
JP2008105979A (en) * | 2006-10-24 | 2008-05-08 | Nippon Kenko Kagaku Kenkyu Center:Kk | Film guard preparation |
JP2013507367A (en) * | 2009-10-08 | 2013-03-04 | エムエスデー・コンシユーマー・ケア・インコーポレイテツド | Low ether composition and delivery device |
KR20140007923A (en) * | 2011-03-25 | 2014-01-20 | 라보라뚜와르 어르고 | Composition containing a cellulose, a vegetable oil and a volatile solvent, and use thereof as a dressing |
JP2014508798A (en) * | 2011-03-25 | 2014-04-10 | ラボラトワール ユルゴ | Composition comprising cellulose, vegetable oil and volatile solvent and use thereof as coating material |
WO2014104149A1 (en) * | 2012-12-28 | 2014-07-03 | 大正製薬株式会社 | Preparation for application to skin |
JPWO2014104149A1 (en) * | 2012-12-28 | 2017-01-12 | 大正製薬株式会社 | Dermal preparation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006326018B2 (en) | Compositions and methods for dermally treating pain | |
US8741333B2 (en) | Compositions and methods for treating dermatitis or psoriasis | |
US8741332B2 (en) | Compositions and methods for dermally treating neuropathic pain | |
CA2633489C (en) | Compositions and methods for treating dermatological conditions | |
JP2735392B2 (en) | How to treat psoriasis | |
US20070189980A1 (en) | Compositions and methods for treating alopecia | |
US20070189977A1 (en) | Spray-on formulations and methods for dermal delivery of drugs | |
US20070189978A1 (en) | Compositions and methods for dermally treating musculoskeletal pain | |
US20120294907A1 (en) | Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs | |
US20070196457A1 (en) | Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs | |
JP2002523144A (en) | Spray to bandage and drug delivery system | |
WO2009017767A2 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
JP2007211030A (en) | Pharmaceutical gel preparation applicable to mucosal surface and body tissue | |
EP1959928A2 (en) | Spray-on formulations and methods for dermal delivery of drugs | |
JPH10152433A (en) | Film-forming antifungal agent composition | |
CN101494976B (en) | Compositions and methods for dermally treating pain | |
CA2633464A1 (en) | Compositions and methods for dermal delivery of drugs | |
JPH07206711A (en) | Composition for treatment of trichophytosis unguium | |
MXPA05013820A (en) | Nail restructuring compositions for topical application. | |
JP2007502326A (en) | Topical treatment of skin symptoms | |
JPH02311414A (en) | Skin drug for external use | |
JPH03204812A (en) | Emulsion containing amino polysaccharide | |
JP2005505593A (en) | Use of tazarotene for preparing nail polish for treating and / or preventing psoriasis, and nail polish containing the same | |
JPS635378B2 (en) | ||
RU2508090C2 (en) | Film coating urea solution for treating nail psoriasis |